The aim of the work is to determine and evaluate the antioxidant activity of dietary supplements with green tea extract, as well as to introduce conditional terms of the level of AOA.
Materials and methods. The object of the study was dietary supplements of different manufactures: “Green Tea Extract” of Natural Sources, USA (DS1), “Extract of green tea” of Elit-Pharm, Ukraine (DS2) and “Green tea” of Pharmakom, Ukraine (DS3). Potentiometric measurements were conducted by pH meter Hanna 2550 (Germany) with a combined platinum electrode EZDO 5010. Epigallocatechin-3-O-gallate ˃98.0 % (Sigma Aldrich), K3[Fe(CN)6], K4[Fe(CN)6], NaHPO4, KH2PO4 were analytical grade.
Results. It was established that a value of the antioxidant activity of DS1 was 36.51 mmol/tab, DS2 – 29.78 mmol/tab, and DS3 – 16.67 mmol/tab. DS1 had the highest value of the antioxidant activity, which correlated with the content of catechins (r2 = 0.9314). According to the proposed conditional terms of antioxidant activity dietary supplements, DS1 and DS2 possessed a low level of antioxidant activity, whereas DS3 corresponded to very low level of antioxidant activity.
Conclusions. It was found that the studied dietary supplements with green tea extract have antioxidant activity, which correlates with the content of catechins.
Мета. Дослідити імуногістохімічні зміни в шкірі хворих із псоріазом для прогнозування можливого загострення шкір- ного псоріатичного процесу після виконання оперативного втручання.
Матеріали і методи. Проведено імуногістохімічне дослідження біопсійного матеріалу, взятого з ділянок шкірної псо- ріатичної висипки та інтактної шкіри у хворих із псоріазом до виконання оперативного втручання. Крім того, для по- рівняння результатів імуногістохімічних досліджень вивчено біопсійний матеріал шкіри передньої черевної стінки, взятий у 5 практично здорових осіб відповідного віку після герніопластики. Для оцінки характеру та поширеності міс- цевих клітинних імунних і запальних реакцій у шкірі хворих із псоріазом застосовували імуногістохімічні методики з визначенням експресії маркерів імунного запалення.
Результати. Представлені результати дослідження змін імуногістохімічної експресії прозапальних біологічних мар- керів у шкірі хворих із псоріазом до виконання оперативного втручання з подальшим аналізом впливу такого стресо- вого фактора, як оперативне втручання, на перебіг шкірного псоріатичного процесу.
Висновки. Доведено, що одним із механізмів загострення запальних реакцій у хворих із псоріазом є активація імуно- компетентних клітин, зокрема через Toll–рецептори, що дає можливість скоригувати тактику лікування пацієнтів у піс- ляопераційному періоді.
Aim: The aim of the study is to analyze the features of the spectrum of lipids of the water-lipid mantle of the skin before and after pathogenetically sound therapy of patients with psoriasis.
Methods: Comparative evaluation of the therapeutic efficacy of monotherapy with the immunobiological drug Humir (adalimumab), as well as its combination with a non-hormonal drug based on natural components Psori Active (cream) in the examined patients with psoriasis vulgaris was performed according to the dynamics of regression of dermatoses clinical manifestations erythema, infiltration, peeling of the skin psoriatic rash, changes in the index PASI, PGA, BSA.
Results: The study involved 137 patients. Changes in the level of other components of the lipid spectrum of the water-lipid mantle of the skin, in particular phospholipids, cholesterol and cholesterol esters in patients of the first observation group changed insignificantly compared to their values before treatment. When comparing the normalization of the level of the studied spectrum of lipids of the water-lipid mantle of the skin in patients of the second group with different seasonal types (autumn-winter, spring-summer, off-season) and previously diagnosed with varying severity treatment, no statistically significant differences were found between seasonal types of dermatosis.
Conclusion: Analysis of the results of clinical follow-up of the examined patients with psoriasis of the first and second groups after completion of treatment and achieving clinical clinical remission indicates significant benefits of systemic immunobiological therapy in combination with topical therapy with Psori Active.
Objective — to conduct an in-depth search of foreign and national literary sources, in particular, reports about the results of randomized controlled clinical trials regarding the use of local combination drugs for the treatment of psoriatic onychodystrophy. The focus is on both short-term and long-term therapeutic effects, as well as minimizing the side effects.
Materials and methods. We conducted the analysis of the world experience of using the local combination drug Onychocid® Emtrix for the treatment of psoriatic onychodystrophy and minimization of side effects by searching for data (2010—2021) in the Cochrane Library controlled tests by keywords: psoriasis, onychodystrophy; in PubMed, High Wire Press, Google Scholar — by terms of the catalog and medical subjects: psoriasis + onychodystrophy + treatment; reports of randomized controlled clinical trials, meta-analyses and literature reviews.
Results and discussion. The modern view on the problem of psoriatic onychodystrophy, methods and approaches to the treatment of this pathology are presented.According to the analysis of the results of foreign and national studies, Onychocid® Emtrix is proved to be clinically efficient and safe as complex treatment for various clinical forms of psoriatic onychodystrophy. It contains a combination of propylene glycol, urea and lactic acid. Active substances, which are part of the drug, are synergists, which provides triple action of ingredients — combining moisturizing and keratolytic effects with antifungal properties. Most patients showed an early (in the 2nd to 4th week of use of the drug) improvement in the appearance of the affected nails. In the future, they observed thinning of nail plates, color restoration, disappearance of excessively keratinized nail tissue, tendency to the restoration of the integrity of nails. The use of this topical medication provided high compliance due to an excellent profile of tolerance and the possibility of application once a day.
Conclusions. It has been proven that the modern medication of local action Onychocid® Emtrix is currently the most optimal treatment for psoriatic onychodystrophy which allows achieving a therapeutic effect both in monotherapy and in the standard complex schemes. Treatment of psoriatic onychodystrophy with Onychocid® Emtrix is more effective in comparison with standard therapy, contributes to a rapid partial or full restoration of the integrity of nail plates. The high effectiveness and safety of Onychocid® Emtrix give reason to recommend it for inclusion in the schemes of complex treatment of patients with psoriatic onychodystophy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.